Drug
Ft836
Ft836: highest development phase Phase 1, developed by Fate Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Fate Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| FT836 NCT07216105 | Phase 1 | Non-Small Cell Lung Cancer |
Latest
No recent events.
Follow Ft836 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.